#eli-lilly

#eli-lilly

We've created a small molecule chemical which gets in your body very well. It can mimic the effects of the peptide and can be taken more conveniently any time of day without any food or water restrictions.

Dividend growth investing builds long-term wealth for retirement by focusing on companies that consistently increase payouts. These stocks provide rising income and often deliver superior total returns through compounding. Research from Hartford Funds, using Ned Davis Research data from 1973 to 2025, shows companies that grew or initiated dividends in the S&P 500 achieved higher average annual returns with lower volatility than non-payers or cutters. Over long periods, dividend growers and initiators outperformed the equal-weighted S&P 500 and demonstrated resilience in market declines.

During a press conference in the Oval Office and surrounded by many of his most senior aides, including HHS Secretary Robert Kennedy, Jr, and Dr. Mehmet Oz, Trump revealed that two of the world's largest pharmaceutical manufacturers, Eli Lilly and Novartis, will offer weight loss drugs at drastic discounts. So far, never heard anything bad about them, only good about them, Trump ad libbed from his prepared remarks before asking his Kennedy, Is there anything bad about them, Bobby?

From late 2020 to the summer of 2024, Eli Lilly & Co. ( NYSE: LLY) stock was on a tear, up more than 635%. Last year was a transformative year for the Indianapolis-based pharmaceutical giant, with substantial financial growth driven by its innovative medicines, significant regulatory successes, and continued investment in its pipeline and manufacturing capabilities. On the other hand, it did experience a revenue shortfall in the fourth quarter.

Eli Lilly (NYSE:LLY) has quickly emerged as one of Wall Street's biggest winners, fueled by explosive demand for its new generation of weight-loss and diabetes treatments. The company's GLP-1 drugs, including Mounjaro and the newly approved Zepbound, have turned into blockbuster products, generating billions in sales and reshaping the pharmaceutical landscape. As a result, Eli Lilly's stock surged more than 50% year-to-date in 2024.

Eli Lilly is on track to become the first healthcare company to reach a $1 trillion market cap, driven by its dominance in the GLP-1 market.

Eli Lilly is suing four telehealth companies for selling illegal copies of its weight-loss drug Zepbound, which is based on the active ingredient tirzepatide.

"The drug also lowered patients' blood sugar levels by 1.3% on average, while the overall efficacy of orforglipron in promoting weight loss and controlling diabetes has been met with enthusiasm."

That's where being a savvy investor comes in. Being contrarian, you can pick up these hidden gems at a significant discount and profit all the way to the bank when their fortunes turn.